Gut Metabolites and Breast Cancer: The Continuum of Dysbiosis, Breast Cancer Risk, and Potential Breast Cancer Therapy
Open Access
- 22 August 2022
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (16) , 9490
Abstract
The complex association between the gut microbiome and cancer development has been an emerging field of study in recent years. The gut microbiome plays a crucial role in the overall maintenance of human health and interacts closely with the host immune system to prevent and fight infection. This review was designed to draw a comprehensive assessment and summary of recent research assessing the anticancer activity of the metabolites (produced by the gut microbiota) specifically against breast cancer. In this review, a total of 2701 articles were screened from different scientific databases (PubMed, Scopus, Embase and Web of Science) with 72 relevant articles included based on the predetermined inclusion and exclusion criteria. Metabolites produced by the gut microbial communities have been researched for their health benefits and potential anticancer activity. For instance, the short-chain fatty acid, butyrate, has been evaluated against multiple cancer types, including breast cancer, and has demonstrated anticancer potential via various molecular pathways. Similarly, nisin, a bacteriocin, has presented with a range of anticancer properties primarily against gastrointestinal cancers, with nominal evidence supporting its use against breast cancer. Comparatively, a natural purine nucleoside, inosine, though it has not been thoroughly investigated as a natural anticancer agent, has shown promise in recent studies. Additionally, recent studies demonstrated that gut microbial metabolites influence the efficacy of standard chemotherapeutics and potentially be implemented as a combination therapy. Despite the promising evidence supporting the anticancer action of gut metabolites on different cancer types, the molecular mechanisms of action of this activity are not well established, especially against breast cancer and warrant further investigation. As such, future research must prioritise determining the dose-response relationship, molecular mechanisms, and conducting animal and clinical studies to validate in vitro findings. This review also highlights the potential future directions of this field.Keywords
Funding Information
- Open Access funding support from Western Sydney University, Australia
This publication has 84 references indexed in Scilit:
- Fecal microbial determinants of fecal and systemic estrogens and estrogen metabolites: a cross-sectional studyJournal of Translational Medicine, 2012
- Nisin, an apoptogenic bacteriocin and food preservative, attenuates HNSCC tumorigenesis via CHAC1Cancer Medicine, 2012
- The immune score as a new possible approach for the classification of cancerJournal of Translational Medicine, 2012
- Epigenetic alterations in the breast: Implications for breast cancer detection, prognosis and treatmentSeminars in Cancer Biology, 2009
- Short-chain fatty acids induce acute phosphorylation of the p38 mitogen-activated protein kinase/heat shock protein 27 pathway via GPR43 in the MCF-7 human breast cancer cell lineCellular Signalling, 2007
- P21WAF1/CIP1 is dispensable for G1 arrest, but indispensable for apoptosis induced by sodium butyrate in MCF-7 breast cancer cellsOncogene, 2004
- Sodium Butyrate Induces G2 Arrest in the Human Breast Cancer Cells MDA-MB-231 and Renders Them Competent for DNA RereplicationExperimental Cell Research, 1999
- Effect of sodium butyrate on human breast cancer cell linesCell Proliferation, 1997
- Effect of sodium butyrate on human breast carcinoma (MCF-7) cellular proliferation, morphology, and CEA productionBreast Cancer Research and Treatment, 1984
- Associated effects of sodium butyrate on histone acetylation and estrogen receptor in the human breast cancer cell line MCF-7Biochemical and Biophysical Research Communications, 1984